ACTION-1 phase Ib/3 trial of RYZ101 in somatostatin receptor subtype 2-expressing (SSTR2+) gastroenteropancreatic neuroendocrine tumors (GEP-NET) progressing after Lu-177 somatostatin analogue (SSA) therapy: Initial safety analysis

JOURNAL OF CLINICAL ONCOLOGY(2023)

引用 0|浏览15
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要